2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

J Steffel, R Collins, M Antz, P Cornu, L Desteghe… - Ep …, 2021 - academic.oup.com
1Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich,
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

J Steffel, P Verhamme, TS Potpara… - European heart …, 2018 - academic.oup.com
The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …

Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care: Second update 2022

S Kietaibl, A Ahmed, A Afshari… - European Journal of …, 2023 - journals.lww.com
Guidelines Management of severe peri-operative bleeding: Guidelines from the European
Society of Anaesthesiology and Intensive Care

[HTML][HTML] Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy …

IM Gralnek, AJ Stanley, AJ Morris, M Camus, J Lau… - …, 2021 - thieme-connect.com
1 ESGE recommends in patients with acute upper gastrointestinal hemorrhage (UGIH) the
use of the Glasgow–Blatchford Score (GBS) for pre-endoscopy risk stratification. Patients …

Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report

GYH Lip, A Banerjee, G Boriani, C en Chiang, R Fargo… - Chest, 2018 - Elsevier
Background The risk of stroke is heterogeneous across different groups of patients with atrial
fibrillation (AF), being dependent on the presence of various stroke risk factors. We provide …

[PDF][PDF] 2017 ESC/EACTS Guidelines for the management of valvular heart disease

H Baumgartner, V Falk, JJ Bax… - Polish Heart …, 2018 - journals.viamedica.pl
Recenzenci dokumentu: Marco Roffi, koordynator recenzji ze strony CPG (Szwajcaria),
Ottavio Alfieri1, koordynator recenzji ze strony EACTS (Włochy), Stefan Agewall (Norwegia) …

[PDF][PDF] 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS)

V Aboyans, JB Ricco, ML Bartelink… - Kardiologia Polska …, 2017 - journals.viamedica.pl
W 2011 roku ESC opublikowało pierwsze wytyczne dotyczące rozpoznawania i leczenia
chorób tętnic obwodowych (PAD)[1]. Ta publikacja wypełniła ważną lukę wśród wytycznych …

2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing …

DJ Kumbhani, CP Cannon, CJ Beavers… - Journal of the American …, 2021 - jacc.org
The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …

JCS/JSCS/JATS/JSVS 2020 guidelines on the management of valvular heart disease

C Izumi, K Eishi, K Ashihara, T Arita, Y Otsuji… - Circulation …, 2020 - jstage.jst.go.jp
The “Guidelines on the Management of Valvular Heart Disease” were initially published as
the “Guidelines on Non-pharmacological Treatment of Valvular Heart Disease” in 2002 …

Idarucizumab for dabigatran reversal—full cohort analysis

CV Pollack Jr, PA Reilly, J Van Ryn… - … England Journal of …, 2017 - Mass Medical Soc
Background Idarucizumab, a monoclonal antibody fragment, was developed to reverse the
anticoagulant effect of dabigatran. Methods We performed a multicenter, prospective, open …